-- Scott Roberts
TUESDAY, Jan. 22 (HealthDay News) -- U.S. Food and Drug
Administration approval of Botox (onabotulinumtoxinA) has been
expanded to include adults with overactive bladder who don't
respond to a class of drugs called anticholinergics.
Overactive bladder's typical symptoms including leakage,
frequent urination and feeling the sudden and urgent need to
urinate. Botox, when injected into the bladder, causes it to relax
and increases its capacity, the FDA said in a news release.
In a clinical study, people treated with Botox after 12 weeks
had urinary incontinence 1.6 to 1.9 times less per day than people
treated with a placebo, the FDA said.
The most common adverse reactions recorded during the study
included urinary tract infection, painful urination and incomplete
bladder emptying (urinary retention). People who develop urinary
retention may have to use a catheter until the situation resolves,
the agency said.
Botox has been approved for several other uses, notably to treat
facial wrinkles. The product is made by Allergan Inc., based in
Medline Plus has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.